MedTrace Logo

CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction

NCT05508256 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1548

Last updated 2023-03-06

No results posted yet for this study

Summary

The objective of CABA-HFPEF is to test whether catheter ablation (CA) for atrial fibrillation (AF) can prevent adverse cardiovascular outcomes in patients with heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF).

Conditions

Interventions

DEVICE

CE-marked Catheter Ablation

Once patients have been randomized to the catheter ablation (CA) group, the ablation procedure must be performed within 4 weeks. CA will initially aim at pulmonary vein isolation.

Sponsors & Collaborators

  • Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

    collaborator OTHER

  • Kompetenznetz Vorhofflimmern e.V. (AFNET)

    collaborator UNKNOWN

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Abdul Parwani, Dr. · Head of Electrophysiology; Charité University Medicine Berlin, CVK

  • Paulus Kirchhof, Prof. Dr. · Director Department of Cardiology, Heart and Vascular Center University Hamburg Eppendorf

  • Stefan Kääb, Prof. Dr. · Department of Cardiology, Ludwig-Maximilians-University Hospital Munich

  • Tim Friede, Prof. Dr. · Departement of Medical Statistics, University Medical Center Göttingen

  • Roland Tilz, Prof. Dr. · Head of Electrophysiology Department, University Hospital Lübeck

  • Burkert Pieske, Prof. Dr. · Independent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2026-07-31
Completion
2027-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05508256 on ClinicalTrials.gov